Article
Medicine, General & Internal
Remi Moirand, Laetitia Imbert, Frederic Haesebaert, Gabrielle Chesnoy, Benoit Bediou, Emmanuel Poulet, Jerome Brunelin
Summary: This study investigated the clinical interest of a 10 session tDCS regimen in patients with mild to severe treatment-resistant depression. The results showed that bifrontal add-on tDCS, combined with antidepressant medication, can be a safe and suitable approach to achieve remission in these patients. However, further studies are needed to confirm these findings in a larger sample size.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Psychology, Clinical
Ole Koehler-Forsberg, Robert Keers, Rudolf Uher, Joanna Hauser, Wolfgang Maier, Marcella Rietschel, Peter McGuffin, Anne E. Farmer, Katherine J. Aitchison, Ole Mors
Summary: This study suggests that there may be correlations between personality traits and antidepressant treatment response, but these correlations may be confounded by differential rates of discontinuation.
PSYCHOLOGICAL MEDICINE
(2023)
Article
Neurosciences
Agnes Norbury, Sarah B. Rutter, Abigail B. Collins, Sara Costi, Manish K. Jha, Sarah R. Horn, Marin Kautz, Morgan Corniquel, Katherine A. Collins, Andrew M. Glasgow, Jess Brallier, Lisa M. Shin, Dennis S. Charney, James W. Murrough, Adriana Feder
Summary: The study suggests that improvements in PTSD symptoms under ketamine treatment are accompanied by changes in brain connectivity, such as increased activity between the ventromedial prefrontal cortex and amygdala. This effect is more pronounced in participants who received ketamine compared to midazolam.
NEUROPSYCHOPHARMACOLOGY
(2021)
Review
Neurosciences
Ashley A. Conley, Amber E. Q. Norwood, Thomas C. Hatvany, James D. Griffith, Kathryn E. Barber
Summary: This meta-analysis evaluated the efficacy of ketamine for major depressive episodes and found significant treatment effects at 2, 4, and 6-weeks post-treatment. The results suggest that ketamine can be an effective pharmacologic intervention with lasting effects up to 6 weeks post-administration, which is promising for treatment outcomes.
PSYCHOPHARMACOLOGY
(2021)
Article
Clinical Neurology
Brittany O'Brien, Marijn Lijffijt, Jaehoon Lee, Ye Sil Kim, Allison Wells, Nicholas Murphy, Nithya Ramakrishnan, Alan C. Swann, Sanjay J. Mathew
Summary: The study used GMM to analyze response trajectories of depressed patients receiving ketamine treatment, revealing three distinct response trajectories. Among severely depressed patients, there were significant differences in antidepressant response to ketamine. Patients with childhood maltreatment and severe baseline depression showed consistent response to ketamine-induced blockade of behavioral sensitization.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Psychiatry
Balwinder Singh, Siamak MahmoudianDehkordi, Jennifer L. Vande Voort, Xianlin Han, John D. Port, Mark A. Frye, Rima Kaddurah-Daouk
Summary: In this pilot study, new insights into the mechanism of action of ketamine were highlighted. The study demonstrated that ketamine rapidly utilizes short-chain acylcarnitines and has broad effects on lipid metabolism, including changes in triglyceride levels. These findings provide novel insights into the action of ketamine and suggest a possible role for mitochondrial function and energy metabolism.
PSYCHIATRY RESEARCH
(2022)
Article
Psychiatry
Mehdi Rezaei, Mohammad Mahdi Shariat Bagheri, Mehdi Ahmadi
Summary: This study investigated the clinical and demographic predictors of therapeutic response in MDD patients receiving tDCS without medications. The results suggested that pronounced sleep disturbances and cognitive-affective symptoms may serve as potential clinical predictors of response to tDCS. Further prospective studies are needed to validate the predictive value of the derived model.
JOURNAL OF PSYCHIATRIC RESEARCH
(2021)
Article
Gastroenterology & Hepatology
Emily C. L. Wong, Parambir S. Dulai, John K. Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula
Summary: This study found that normal levels of C-reactive protein and albumin in serum, as well as baseline endoscopic severity, can affect placebo response rates in clinical trials of ulcerative colitis. These findings have implications for the design of future clinical trials in this condition.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Clinical Neurology
Brittany O'Brien, Jaehoon Lee, Seungman Kim, Guriqbal S. Nandra, Prabhneet Pannu, Alan C. Swann, Nicholas Murphy, Amanda J. F. Tamman, Dania Amarneh, Marijn Lijffijt, Lynnette A. Averill, Sanjay J. Mathew
Summary: The goal of this study was to replicate previous findings of three distinct treatment response pathways associated with repeated intravenous (IV) ketamine infusions among patients with major depressive disorder (MDD). The results showed that only about a third of depressed patients benefited significantly from an acute induction course of ketamine infusions.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Psychiatry
Xiaofeng Lan, Yanling Zhou, Chengyu Wang, Weicheng Li, Fan Zhang, Haiyan Liu, Ling Fu, Kai Wu, Roger S. McIntyre, Yuping Ning
Summary: This study found that in depression patients with severe pain, significant improvement in depressive symptoms was observed after six ketamine infusions, while patients with mild pain or no pain showed lower improvement.
FRONTIERS IN PSYCHIATRY
(2022)
Article
Clinical Neurology
Ana Paula Jesus-Nunes, Gustavo C. Leal, Fernanda S. Correia-Melo, Flavia Vieira, Rodrigo P. Mello, Ana Teresa Caliman-Fontes, Mariana V. F. Echegaray, Roberta F. Marback, Livia N. F. Guerreiro-Costa, Breno Souza-Marques, Cassio Santos-Lima, Lucca S. Souza, Igor D. Bandeira, Flavio Kapczinski, Acioly L. T. Lacerda, Lucas C. Quarantini
Summary: The study identified that the number of treatment failures and severity of illness were predictors of fewer remissions and responses of depressive symptoms in TRD patients. This finding suggests that understanding these predictors may help in better patient selection for ketamine treatment.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
(2022)
Review
Biochemistry & Molecular Biology
Gustavo C. Medeiros, Todd D. Gould, William L. Prueitt, Julie Nanavati, Michael F. Grunebaum, Nuri B. Farber, Balwinder Singh, Sudhakar Selvaraj, Rodrigo Machado-Vieira, Eric D. Achtyes, Sagar V. Parikh, Mark A. Frye, Carlos A. Zarate, Fernando S. Goes
Summary: (R,S)-ketamine and (S)-ketamine have rapid and substantial antidepressant effects, but there is no well-accepted method to differentiate responders from non-responders. The association between blood-based biomarkers and response to ketamine was examined in a systematic review/meta-analysis, revealing limited evidence of a consistent relationship.
MOLECULAR PSYCHIATRY
(2022)
Article
Medicine, General & Internal
Yu-Wei Lin, Yu-Kang Tu, Kuo-Chuan Hung, Chih-Sung Liang, Ping-Tao Tseng, Pao-Yen Lin, Edward Chia-Cheng Lai, Chih-Wei Hsu
Summary: Zuranolone, a promising antidepressant, has been found to effectively alleviate depression and anxiety symptoms. However, it is associated with potential side effects. A daily dose of 30 mg appears to be the optimal choice.
Review
Pharmacology & Pharmacy
Ruidong Ding, Dingyuan Su, Qian Zhao, Yu Wang, Jia-Yi Wang, Shuangyu Lv, Xinying Ji
Summary: Major depressive disorder (MDD) is a growing global psychiatric disorder that severely impacts physical and mental health, leading to disability and suicide. The complex pathogenesis of depression has hindered the development of effective diagnostics and treatments. Recent research has focused on the role of microRNAs, short non-coding RNAs found at high levels in brain tissues, in depression. These microRNAs have been found to regulate the pathophysiology of depression, including the dysregulation of monoamines, neuroplasticity and neurogenesis abnormalities, hyperactivity of the HPA axis, and dysregulation of inflammatory responses. They may provide new insights for the diagnosis, treatment, and development of antidepressant drugs for MDD.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Neurosciences
Vasileia Kotoula, Argyris Stringaris, Nuria Mackes, Ndabezinhle Mazibuko, Peter C. T. Hawkins, Maura Furey, H. Valerie Curran, Mitul A. Mehta
Summary: This study demonstrates that detectable changes in reward-related brain areas can occur 2 hours after ketamine infusion, suggesting a potential mechanism for ketamine's improvement of reward-related symptoms.
BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING
(2022)
Article
Clinical Neurology
Michael Cronquist Christensen, Roger S. McIntyre, Ioana Florea, Henrik Loft, Andrea Fagiolini
Summary: This study analyzed the efficacy and tolerability of vortioxetine in patients with major depressive disorder. The results showed that vortioxetine 20 mg/day was more effective than 10 mg/day, with similar tolerability. In flexible-dose studies, nearly half of the patients received 20 mg/day after 1 week and two-thirds received 20 mg/day as their final dosage.
Review
Clinical Neurology
Roger S. Mcintyre, Leslie Citrome, Hannah Cummings, Mark S. Todtenkopf, Laura A. Tan, Marni White, Sarah Akerman
Summary: The endogenous opioid system plays an important role in weight and metabolism regulation. Targeting this system may help mitigate antipsychotic-induced weight gain and metabolic dysregulation.
Article
Clinical Neurology
Houman Rashidian, Mehala Subramaniapillai, Caroline Park, Orly Lipsitz, Hannah Zuckerman, Bing Cao, Yena Lee, Hartej Gill, Roger Nelson Rodrigues, Joshua D. Di Vincenzo, Michelle Iacobucci, Saja Jaberi, Joshua D. Rosenblat, Roger S. McIntyre, Rodrigo B. Mansur
Summary: This study assessed changes in insulin resistance (IR) after antidepressant treatment and found that exacerbation of IR mediated non-response to treatment. In contrast, responders showed a reduction in IR. These findings further elucidate the role of IR in antidepressant response.
JOURNAL OF PSYCHOPHARMACOLOGY
(2023)
Article
Psychiatry
Runhua Wang, Yuanyuan Cai, Weicong Lu, Ruoxi Zhang, Robin Shao, Suk-Yu Yau, Brendon Stubbs, Roger S. McIntyre, Kuan-Pin Su, Guiyun Xu, Liangwen Qi, Kwok-Fai So, Kangguang Lin
Summary: This 3-month randomized psychoeducation-controlled trial examined the effects of exercise on gut microbiota in young adolescents with subthreshold depression. The exercise intervention group showed an increase in the relative abundance of certain genera and species of gut bacteria compared to the psychoeducation-controlled group. These changes were associated with improvements in depressive symptoms and enrichment of defense and signal transduction mechanisms.
PSYCHIATRY RESEARCH
(2023)
Review
Psychiatry
Shakila Meshkat, Sipan Haikazian, Joshua D. Di Vincenzo, Farhan Fancy, Danica Johnson, David Chen-Li, Roger S. McIntyre, Rodrigo Mansur, Joshua D. Rosenblat
Summary: This systematic review evaluates the efficacy, tolerability, and safety of oral ketamine, esketamine, and r-ketamine for unipolar and bipolar depression. The results indicate significant antidepressant effects and good tolerability of oral ketamine. However, the included randomized controlled trials had a high risk of bias, and further research with larger sample sizes and longer follow-up periods is needed to determine the antisuicidal effects and efficacy in treatment-resistant depression.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
(2023)
Article
Clinical Neurology
Roger S. McIntyre, Suresh Durgam, Susan G. Kozauer, Richard Chen, Jason Huo, Robert E. Davis, Andrew J. Cutler
Summary: A recent Phase 3 study showed that lumateperone 42 mg monotherapy effectively improved symptoms of depression in patients with bipolar depression. The study analyzed the change in MADRS scores and found significant improvements in individuals with bipolar I and bipolar II disorder.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Review
Clinical Neurology
Giacomo d'Andrea, Mauro Pettorruso, Giorgio Di Lorenzo, Gianluca Mancusi, Roger S. McIntyre, Giovanni Martinotti
Summary: Ketamine and esketamine have generated significant interest as potential therapeutic agents for Treatment-Resistant Depression (TRD). This article provides a comprehensive overview of their action and highlights their effectiveness on mixed features, anxiety, dysphoric mood, and bipolar traits. The complex pharmacodynamic mechanisms of action are discussed, and further research is needed to evaluate the efficacy of esketamine nasal spray in bipolar depression and the potential role of these substances as mood stabilizers.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Danica E. Johnson, Roger S. McIntyre, Rodrigo B. Mansur, Joshua D. Rosenblat
Summary: Cognitive impairment is a significant feature of bipolar disorder, affecting recovery and quality of life. While there are currently no effective treatments for cognitive impairment in bipolar disorder, various pharmacological interventions are being explored as potential options that target the underlying pathophysiology of the disorder.
EXPERT OPINION ON PHARMACOTHERAPY
(2023)
Article
Clinical Neurology
Jingman Shi, Xue Han, Yuhua Liao, Hao Zhao, Beifang Fan, Huimin Zhang, Kayla M. Teopiz, Weidong Song, Lingjiang Li, Lan Guo, Ciyong Lu, Roger S. McIntyre
Summary: This study examined the association between stressful life events (SLEs) and subthreshold depressive symptoms (SDS) and major depressive disorder (MDD), with a focus on gender effects. The findings showed that individuals who experienced any SLEs were at a higher risk of SDS and MDD. The association between SLEs and SDS was stronger in females, while the association between SLEs and MDD was stronger in males.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Clinical Neurology
Mi Kyoung Seo, Sehoon Jeong, Dae-Hyun Seog, Jung An Lee, Jae-Hon Lee, Yena Lee, Roger S. McIntyre, Sung Woo Park, Jung Goo Lee
Summary: This study investigated the effects of liraglutide, a GLP-1 agonist, on a depression-like phenotype in mice exposed to chronic unpredictable stress. Liraglutide treatment reduced immobility in the forced swim test and improved cognitive function in the Morris water maze test. These results suggest that GLP-1 agonists could be potential novel antidepressants.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Clinical Neurology
Yanzhi Li, Lu Cheng, Lan Guo, Liwan Zhu, Hao Zhao, Caiyun Zhang, Manjun Shen, Yifeng Liu, Muhammad Youshay Jawad, Lingjiang Li, Wanxin Wang, Ciyong Lu, Roger S. McIntyre
Summary: This study explores the mediating role of personality traits in the relationship between adverse childhood experiences (ACEs) and depressive symptoms in older adults. The results suggest that maltreatment and household dysfunction induce depressive symptoms by increasing neuroticism, while poor parent-child bonding induces depressive symptoms by increasing neuroticism and reducing conscientiousness and extraversion.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Review
Genetics & Heredity
Jiangbo Ying, Qian Hui Chew, Roger S. McIntyre, Kang Sim
Summary: Treatment-resistant schizophrenia (TRS) is difficult to treat and has a negative impact on patients' quality of life. Clozapine is effective for TRS but has side effects. This review summarizes the current genetic factors associated with TRS, clozapine resistance, and side effects. Further research is needed to identify risk genes and understand the interactions between genes and relevant clinical factors in TRS treatment.
Article
Psychiatry
Xiuwen Li, Huimin Zhang, Xue Han, Lan Guo, Felicia Ceban, Yuhua Liao, Jingman Shi, Wanxin Wang, Yifeng Liu, Weidong Song, Dongjian Zhu, Hongqiong Wang, Lingjiang Li, Beifang Fan, Ciyong Lu, Roger S. McIntyre
Summary: This study explored the association between somatic symptoms and subthreshold depression (SD) and Major Depressive Disorder (MDD), and determined the predictive potential of somatic symptoms in identifying SD and MDD in primary care. The results showed that somatic symptoms were associated with the presence of SD and MDD, and energy-related symptoms had good predictive potential.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Biochemistry & Molecular Biology
Vincent Chin-Hung Chen, Shao-Lan Huang, Jing-Yu Huang, Tsai-Ching Hsu, Bor-Show Tzang, Roger S. Mcintyre
Summary: The combination of Nivolumab and Escitalopram oxalate was found to have synergistic effects in inhibiting the proliferation of liver cancer cells. This study highlights the potential of combined drug therapy as an alternative treatment option for liver cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Joshua D. D. Rosenblat, Froukje E. E. deVries, Zoe Doyle, Roger S. S. McIntyre, Gary Rodin, Camilla Zimmermann, Ernie Mak, Breffni Hannon, Christian Schulz-Quach, Aida Al Kindy, Zeal Patel, Madeline Li
Summary: Ketamine administered through intranasal spray has shown rapid and sustained antidepressant effects in advanced cancer patients suffering from moderate to severe depression. The treatment was well-tolerated with minimal side effects. Further larger-scale controlled trials are needed to confirm these promising findings.